View
295
Download
4
Tags:
Embed Size (px)
DESCRIPTION
El Dr. Juan F. Ascaso, presidente de la Sociedad Española de la Arteriosclerosis (SEA), participa en el acto de presentación de la 'Jornada Galáctica sobre Guías de Lípidos y objetivos a alcanzar en los pacientes de más alto riesgo cardiovascular' (Málaga, 4-5 abril, 2014). Accede a la jornada completa en http://guiaslipidos.secardiologia.es
Citation preview
- Know CVD
- Type 2 diabetes mellitus o Type 1 with microalbuminuria.
- Markedly elevated single risk factors (HF, severe hypertension,…)
- Chronic kidney disease
- Score of high risk
2003 Framingham and ATPIII 10-year risk of CVD event of ≥20%
2012 SCORE (European Societies) 10-year risk of CVD death of ≥5%
2013 IAS Estimation of total CVD morbidity by age 80 ≥45%
2013 ACC/AHA estimated 10-year ASCVD risk ≥7.5%
(40 to 75 years of age with LDL-C ≥70 mg/dL)Juan F Ascaso
0
10
20
30
40
50
60
70
80
90
100
Categoría 1
High
Intermediate
Low
CVR
20,0
60,7
19,3
European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice, aged 50-65 years free of diabetes and not receiving lipid-lowering therapy
EURIKA Eur J Prev Cardiol 2013 Juan F Ascaso
Population
Intermediate Risk
No event Intermediate Risk
Event
High Risk
Death
Death
High Risk
High Risk
Modified. Perman G et al. Cost Eff Resour Alloc. 2011; 9: 4. Juan F Ascaso
No event
Event
High Risk
Death
Death
Europa Risk SCORE 1-4
USA 40-75 y, LDL-C 70-189 mg/dL, Risk 5-7,5
is modulated by
- Family history of premature CVD, which is considered to increase the risk by 1.7-fold in women and by 2.0-fold in men.
- Abdominal obesity- Physical activity pattern, - Low HDL-C and high TG, - hs-CRP, - Lp(a), - Fibrinogen,- Homocysteine, - Apo B,- Social class.Conversely, risk may be lower than indicated in those with very high HDL-C levels or a family history of longevity.
- LDL–C ≥160 mg/dL or other evidence of genetic hyperlipidemias
- Family history of premature ASCVD in a first degree relative, with onset <55 y in male or <65 y in female
- Hs-CRP >2 mg/L - CAC score ≥300 Agatston units or ≥75
percentile for age, sex, and ethnicity, - Ankle-brachial index <0.9, - Elevated lifetime risk of ASCVD. - Additional factors may be identified in the
future.
Juan F Ascaso
- Diabetes
- Markedly elevated single risk factors
- Chronic kidney disease
- Association of risk factors
Huxley, R. et al. BMJ 2006;332:73-78
14%
Juan F Ascaso
- Diabetes
- Markedly elevated single risk factors
- Chronic kidney disease
- Association of risk factors
Versmissen J et al. BMJ 2008;337:a2423.Skoumas et al. Circ J 2013; 77:163-8
2%
HF Familial HypercholesterolemiaFCH Familial Combined Hyperlipidemia
FHFCH
0,5%
Juan F Ascaso
9,8% 56.6% women mean age, 57.1 y
- Diabetes
- Markedly elevated single risk factors
- Chronic kidney disease
- Association of risk factors
IDHOCO. PLoS Med. 2014; 11(1): e1001591
≥160/≥100 mm HgSevere hypertension
Juan F Ascaso
- Diabetes
- Markedly elevated single risk factors
- Chronic kidney disease
- Association of risk factors
7,0% eGFR <60
Di Angelantonio et al. BMJ 2010;341:c4986
0,2%,eGFR <45
>45 y
Juan F Ascaso
- Diabetes
- Markedly elevated single risk factors
- Chronic kidney disease
- Association of risk factorsOB 25%
The Emerging Risk Factors Collaboration. Lancet 2011; 377: 1085–95
OW 50%
Juan F Ascaso
Modified. INTERHEART Study. Lancet 2004; 364: 937-972
51
225
612
864
32
16
8
4
2
1
(1) (2) (3) (4)Smk DM HTN ApoB/A 1+2+3 All4 +Obes +PS AllRFs
Od
ds
rati
o (
99
%C
I)
2.9(2.6-3.2) 2.4
(2.1-2.7)1.9
(1.7-2.1)
3.3(2.8-3.8)
13.0(10.7-15.8)
42.3(33.2-54.0)
68.5(53.0-88.6)
182.9(132-252)
333.7(230-483)
In 27 000 participants from 52 countries in INTERHEART
Juan F Ascaso
ECV aterosclerosa, especialmente EC, es la primera causa de
muerte prematura en todo el mundo.
ECV afecta a hombres y mujeres.
En europeos <75 años la ECV representa:
- El 42% de todas las causas de muerte en mujeres
- El 38% de todas las causas de muerte en hombres
Eur Heart J 2012
La reducción de la mortalidad por ECV se relaciona con una
intervención adecuada con
- cambios en el estilo de vida
- tratamiento farmacológico
Juan F Ascaso
Juan F Ascaso